Orbsen Therapeutics is a stromal cell immunotherapy company based in Galway, Ireland. Using proprietary GMP-compliant and scalable positive-selection purification strategies, we are developing ground-breaking, second generation stromal cell treatments to address some of today’s most challenging diseases. Stromal cell immunotherapy holds great promise as an alternative to drugs and surgical procedures for treating a wide range of medical conditions including acute inflammatory disease, arterial disease of the limbs, diabetes complications, arthritis and other inflammatory conditions. This treatment potential is linked to stromal cells’ natural capacity to modulate the immune system, limit inflammation and promote healing, repair and regeneration of damaged tissues. The cells can be selected from single or pooled donors, and expanded and frozen to generate significant numbers of well characterized, “off-the-shelf” allogeneic products. Clinical trials in patients suffering from diabetic foot ulcers, autoimmune liver disease, diabetic kidney disease and acute respiratory distress syndrome are beginning.